Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7C31

Crystal structure of the grapevine defensin VvK1

7C31 の概要
エントリーDOI10.2210/pdb7c31/pdb
分子名称Knot1 domain-containing protein (2 entities in total)
機能のキーワードcysteine-rich, antimicrobial, antifungal, immunomodulatory, plant defensin, antimicrobial protein
由来する生物種Vitis vinifera (Grape)
タンパク質・核酸の鎖数2
化学式量合計10476.32
構造登録者
Chen, M.W.,Chang, S.C.,Chandy, K.G.,Luo, D. (登録日: 2020-05-10, 公開日: 2020-09-16, 最終更新日: 2024-10-16)
主引用文献Ong, S.T.,Bajaj, S.,Tanner, M.R.,Chang, S.C.,Krishnarjuna, B.,Ng, X.R.,Morales, R.A.V.,Chen, M.W.,Luo, D.,Patel, D.,Yasmin, S.,Ng, J.J.H.,Zhuang, Z.,Nguyen, H.M.,El Sahili, A.,Lescar, J.,Patil, R.,Charman, S.A.,Robins, E.G.,Goggi, J.L.,Tan, P.W.,Sadasivam, P.,Ramasamy, B.,Hartimath, S.V.,Dhawan, V.,Bednenko, J.,Colussi, P.,Wulff, H.,Pennington, M.W.,Kuyucak, S.,Norton, R.S.,Beeton, C.,Chandy, K.G.
Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin.
Acs Pharmacol Transl Sci, 3:720-736, 2020
Cited by
PubMed Abstract: We describe a cysteine-rich, membrane-penetrating, joint-targeting, and remarkably stable peptide, EgK5, that modulates voltage-gated K1.3 potassium channels in T lymphocytes by a distinctive mechanism. EgK5 enters plasma membranes and binds to K1.3, causing current run-down by a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. EgK5 exhibits selectivity for K1.3 over other channels, receptors, transporters, and enzymes. EgK5 suppresses antigen-triggered proliferation of effector memory T cells, a subset enriched among pathogenic autoreactive T cells in autoimmune disease. PET-CT imaging with F-labeled EgK5 shows accumulation of the peptide in large and small joints of rodents. In keeping with its arthrotropism, EgK5 treats disease in a rat model of rheumatoid arthritis. It was also effective in treating disease in a rat model of atopic dermatitis. No signs of toxicity are observed at 10-100 times the dose. EgK5 shows promise for clinical development as a therapeutic for autoimmune diseases.
PubMed: 32832873
DOI: 10.1021/acsptsci.0c00035
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.3 Å)
構造検証レポート
Validation report summary of 7c31
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon